Emerging as a noteworthy advance in the struggle against obesity, this medication is generating considerable buzz. This treatment combines properties of two known GLP-1 receptor agonists, liraglutide, plus an additional glucose-dependent incretin component. Preliminary patient data have indicated substantial fat decrease in patients with excessi… Read More